In the past week, LFCR stock has gone up by 9.77%, with a monthly decline of -1.23% and a quarterly surge of 10.20%. The volatility ratio for the week is 5.21%, and the volatility levels for the last 30 days are 9.96% for Lifecore Biomedical Inc The simple moving average for the past 20 days is 13.87% for LFCR’s stock, with a -8.71% simple moving average for the past 200 days.
Is It Worth Investing in Lifecore Biomedical Inc (NASDAQ: LFCR) Right Now?
The price-to-earnings ratio for Lifecore Biomedical Inc (NASDAQ: LFCR) is above average at 24.23x. The 36-month beta value for LFCR is also noteworthy at 0.93. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for LFCR is 28.05M, and at present, short sellers hold a 10.24% of that float. The average trading volume of LFCR on September 20, 2024 was 299.93K shares.
LFCR) stock’s latest price update
Lifecore Biomedical Inc (NASDAQ: LFCR) has experienced a rise in its stock price by 8.08 compared to its previous closing price of 5.20. However, the company has seen a gain of 9.77% in its stock price over the last five trading days. accesswire.com reported 2024-09-19 that LOS ANGELES, CA / ACCESSWIRE / September 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. (“Lifecore” or “the Company”) (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company’s securities between October 7, 2020 and March 19, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before September 27, 2024.
Analysts’ Opinion of LFCR
Many brokerage firms have already submitted their reports for LFCR stocks, with Craig Hallum repeating the rating for LFCR by listing it as a “Buy.” The predicted price for LFCR in the upcoming period, according to Craig Hallum is $8 based on the research report published on September 05, 2024 of the current year 2024.
Stephens gave a rating of “Equal-Weight” to LFCR, setting the target price at $2 in the report published on March 20th of the previous year.
LFCR Trading at 5.96% from the 50-Day Moving Average
After a stumble in the market that brought LFCR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.85% of loss for the given period.
Volatility was left at 9.96%, however, over the last 30 days, the volatility rate increased by 5.21%, as shares sank -1.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.69% upper at present.
During the last 5 trading sessions, LFCR rose by +9.77%, which changed the moving average for the period of 200-days by -23.64% in comparison to the 20-day moving average, which settled at $4.93. In addition, Lifecore Biomedical Inc saw -9.21% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for LFCR
Current profitability levels for the company are sitting at:
- -0.06 for the present operating margin
- 0.33 for the gross margin
The net margin for Lifecore Biomedical Inc stands at 0.09. The total capital return value is set at -0.03. Equity return is now at value 20.97, with 3.46 for asset returns.
Based on Lifecore Biomedical Inc (LFCR), the company’s capital structure generated 0.7 points at debt to capital in total, while cash flow to debt ratio is standing at -0.0. The debt to equity ratio resting at 2.33. The interest coverage ratio of the stock is -0.4.
Currently, EBITDA for the company is 0.81 million with net debt to EBITDA at 40.38. When we switch over and look at the enterprise to sales, we see a ratio of 2.3. The receivables turnover for the company is 4.12for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.08.
Conclusion
In summary, Lifecore Biomedical Inc (LFCR) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
